ALRIB.PA

Riber S.A

ALRIB.PA, France

Riber S.A. provides molecular beam epitaxy (MBE) products and related services for the compound semiconductor research and industrial field. The company offers MBE systems, such as research and pilot production systems, real-time curvature measurement products, and laser passivation tools; and MBE sources, including effusion cells, gas and valved sources, resistive cells, and valved cracker sources, as well as MBE heaters and manipulators. It also provides MBE accessories and services, OEM components and systems, and software products. The company serves power and RF electronics, lasers, IR detectors, displays, passivation, materials, solar, and OEM markets. The company was founded in 1964 and is based in Bezons, France.

https://www.riber.com

Stock Price

€0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ALRIB.PA
stock
ALRIB.PA

ALRIB.PA Riber S.A. EURONEXT: Shares +15.55% to €4.83 on heavy volume, earnings ahead Meyka

Read more →
ALRIB.PA
stock
ALRIB.PA

Riber S.A. (EPA:ALRIB) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable simplywall.st

Read more →

Showing 2 of 4

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

0

Buy

1

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

23.37

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

3.67

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-3.85 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-1.67 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-20.78 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.30

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Riber S.A

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(7)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

€ 0

Short Term Investments

€ 0

Receivables

€ 0

Inventories

€ 0

Total Current Assets

€ 0

Property Plant Equipment

€ 0

Total Assets

€ 0

Payables

€ 0

Short Term Debt

€ 0

Long Term Debt

€ 0

Total Liabilities

€ 0

Equity

€ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

€ 0

Depreciation

€ 0

Change In Working Capital

€ 0

Cash From Operations

€ 0

Capital Expenditures

€ 0

Cash From Investing

€ 0

Cash From Financing

€ 0

Net Change In Cash

€ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.